Eterna Therapeutics Inc.(ERNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ERNA Eterna Therapeutics Inc.

Pre-Mkt 08-31 08:59:03 EDT

4.57

-0.16

-3.48%

盘前4.70

+0.13+2.81%

06:46 EDT

High4.99	Low4.56	Vol26.57K
Open4.76	D1 Closing4.74	Amplitude9.08%
Mkt Cap7.46M	Tradable Cap5.56M	Total Shares1.63M
T/O124.29K	T/O Rate2.19%	Tradable Shares1.22M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ERNA","market":"US","secType":"STK","nameCN":"Eterna Therapeutics Inc.","latestPrice":4.57,"timestamp":1787947200000,"preClose":4.735,"halted":0,"volume":26574,"hourTrading":{"tag":"盘前","latestPrice":4.6984,"preClose":4.57,"latestTime":"06:46 EDT","volume":33,"amount":155.096799,"timestamp":1788173202023,"change":0.1284,"changeRate":0.028096,"amplitude":0.00035},"delay":0,"changeRate":-0.03484688489968322,"floatShares":1216200,"shares":1632400,"eps":-18.605883,"marketStatus":"Pre-Mkt","change":-0.165,"latestTime":"08-31 08:59:03 EDT","open":4.76,"high":4.9899,"low":4.56,"amount":124285.588188,"amplitude":0.090792,"askPrice":5.16,"askSize":100,"bidPrice":4,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-18.605883,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788183000000},"marketStatusCode":1,"adr":0,"listingDate":465451200000,"exchange":"NASDAQ","adjPreClose":4.57,"preHourTrading":{"tag":"盘前","latestPrice":4.6984,"preClose":4.57,"latestTime":"06:46 EDT","volume":33,"amount":155.096799,"timestamp":1788173202023,"change":0.1284,"changeRate":0.028096,"amplitude":0.00035},"postHourTrading":{"tag":"盘后","latestPrice":4.57,"preClose":4.57,"latestTime":"19:44 EDT","volume":502,"amount":2260.0467,"timestamp":1787960699533,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5763514724771831},"requestUrl":"/m/hq/s/ERNA/tweets","defaultTab":"tweets","newsList":[{"id":"2662090031","title":"Ernexa Therapeutics Director David Polinsky Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2662090031","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662090031?lang=en_us&edition=fundamental","pubTime":"2026-08-28 07:53","pubTimestamp":1787874802,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics director David Polinsky files initial beneficial ownership statementDirector David Polinsky reported 8,000 Ernexa Therapeutics common shares held indirectly through Polo3K, LLC in ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL12SfH0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662202700","title":"Ernexa Therapeutics Posts On-Demand Video Webcast of Investor Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2662202700","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662202700?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:02","pubTimestamp":1787835772,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics posts on-demand video webcast of investor presentationErnexa Therapeutics published an on-demand video webcast presentation from a Virtual Investor “Why Now” conference. LinkPresen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDLcbsMZL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU0314104364.USD","BCDF","ERNA","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","IE00BQXX3D17.EUR","SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","BK4139","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4585","IE00BQXX3F31.USD","BK4588","IE00BQXX3C00.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658993909","title":"Press Release: Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993909","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658993909?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:01","pubTimestamp":1786366860,"startTime":"0","endTime":"0","summary":"Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governanceAppointment further streng","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4588","BBP","RFL","SYNB","BK4205","IND","LENZ","BK4581","BK4233","BK4007","ERNA","XBI","BK4585","IBB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657621266","title":"Ernexa Therapeutics Inc Expected to Post a Loss of $3.84 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657621266","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657621266?lang=en_us&edition=fundamental","pubTime":"2026-08-08 06:51","pubTimestamp":1786143065,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics Inc <ERNA.OQ> expected to post a loss of $3.84 a share - Earnings PreviewErnexa Therapeutics IncERNA.OQERNA.Ois expected to  report resultson November 5  for the period ending September 30 2026LSEG's mean analyst estimate for Ernexa Therapeutics Inc is for a loss of $3.84 per share.The one available analyst rating on the shares is \"buy\".The mean earnings estimate of analysts had fallen by about 56.4% in the last three months. Wall Street's median 12-month price target for Ernexa Therapeutics Inc is $30.00, about 612.6% above its last closing price of $4.21This summary was machine generated August 7 at 22:51 GMT.  All figures in US dollars unless otherwise stated.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4442OE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657669117","title":"Ernexa Q2 Net Loss Widens to $4.01 Million; Reports no Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2657669117","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657669117?lang=en_us&edition=fundamental","pubTime":"2026-08-07 06:21","pubTimestamp":1786054899,"startTime":"0","endTime":"0","summary":"Ernexa Q2 net loss widens to $4.01 million; reports no revenueErnexa posted a net loss of USD 4.01 million for the quarter ended June 30, 2026, widening from USD 3.14 million a year earlier.Operating ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL6tZypZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653087260","title":"Ernexa CEO Says Erna-101 Aims to Boost Combination Immunotherapy in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2653087260","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653087260?lang=en_us&edition=fundamental","pubTime":"2026-07-24 21:20","pubTimestamp":1784899228,"startTime":"0","endTime":"0","summary":"Ernexa CEO says ERNA-101 aims to boost combination immunotherapy in solid tumorsErnexa management outlined a strategy to position ERNA-101 as a combination partner for immunotherapies by targeting the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDLKtbt4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","LU2095319765.USD","BK4139","BK4585","NDAQ","LU2210150020.SGD","SG9999014021.USD","LU0314104364.USD","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","BCDF","ERNA","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SG9999014039.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653801210","title":"Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2653801210","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653801210?lang=en_us&edition=fundamental","pubTime":"2026-07-24 21:20","pubTimestamp":1784899200,"startTime":"0","endTime":"0","summary":"CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically \"Cold\" Tumors Into Targets for the Immune System  Video Show","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/24/3332875/0/en/Ernexa-Therapeutics-CEO-Corner-Emphasizes-How-ERNA-101-Could-Help-Unlock-the-Next-Generation-of-Combination-Cancer-Therapies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651266466","title":"NASDAQ Trade Halt Volatility Trading Pause at 09:39 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2651266466","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651266466?lang=en_us&edition=fundamental","pubTime":"2026-07-15 21:39","pubTimestamp":1784122769,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 09:39 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nAQN2M857Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651646874","title":"Ernexa Therapeutics announces new ERNA-101 preclinical data","url":"https://stock-news.laohu8.com/highlight/detail?id=2651646874","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651646874?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:15","pubTimestamp":1784117721,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics (ERNA) announced new preclinical data independently validating the anti-tumor activity of its lead cell therapy candidate, ERNA...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-announces-new-erna-101-preclinical-data-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-announces-new-erna-101-preclinical-data-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBBQ","CNCR","ERNA","IBB","BK4139","BK4588","BK4585","GNOM","SYNB","LFSC","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651450470","title":"Ernexa Says Erna-101 Plus Anti-pd-1 Clears Tumors in Ovarian Cancer Preclinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2651450470","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651450470?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:50","pubTimestamp":1784116218,"startTime":"0","endTime":"0","summary":"Ernexa says ERNA-101 plus anti-PD-1 clears tumors in ovarian cancer preclinical studyErnexa reported independent CRO validation of ERNA-101 combined with anti-PD-1 in an ovarian cancer model.Combinati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL7twrfS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","IE00BKPKM429.USD","SG9999014021.USD","IE00BGHQF748.EUR","ERNA","LU2095319765.USD","BK4585","NDAQ","SG9999014013.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","BCDF","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","BK4588","LU2210150020.SGD","BK4139","LU0314104364.USD","SG9999014039.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651504214","title":"Ernexa Therapeutics - on Track for Ind Submission Q3 2026 and Phase 1 Trial Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2651504214","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651504214?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:50","pubTimestamp":1784116211,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H18I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651422450","title":"Ernexa Therapeutics - Plans Ind Submission for Q3 2026; Phase 1 Trial Expected to Begin Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2651422450","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651422450?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:50","pubTimestamp":1784116211,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H18I:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651345047","title":"Ernexa Therapeutics - no Complete Tumor Clearance Observed with Erna-101 or Anti-pd-1 Monotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2651345047","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651345047?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:50","pubTimestamp":1784116211,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H18I:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651106937","title":"Ernexa Therapeutics CEO Corner Highlights Differentiated Erna-101 Platform as Company Advances Toward Planned First-in-human Phase 1 Study in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2651106937","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651106937?lang=en_us&edition=fundamental","pubTime":"2026-07-14 21:01","pubTimestamp":1784034060,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nTUAC0W9DG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651109430","title":"Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2651109430","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651109430?lang=en_us&edition=fundamental","pubTime":"2026-07-14 21:01","pubTimestamp":1784034060,"startTime":"0","endTime":"0","summary":"CEO discusses ERNA-101's potential to transform immunologically \"cold\" tumors into tumors the immune system can recognize and kill  Video highlights compelling preclinical data, differentiated off-the","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/14/3326943/0/en/Ernexa-Therapeutics-CEO-Corner-Highlights-Differentiated-ERNA-101-Platform-as-Company-Advances-Toward-Planned-First-in-Human-Phase-1-Study-in-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648337556","title":"Ernexa Therapeutics Holds Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2648337556","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648337556?lang=en_us&edition=fundamental","pubTime":"2026-07-03 04:32","pubTimestamp":1783024364,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics holds annual shareholder meetingErnexa Therapeutics held its annual stockholder meeting on July 1, 2027.Stockholders elected five directors to serve until the 2027 annual meeting.A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL42FyvX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646497360","title":"Ernexa Therapeutics SVP of Finance Sandra Gurrola Resigns Effective July 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2646497360","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646497360?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:31","pubTimestamp":1782505888,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics SVP of Finance Sandra Gurrola resigns effective July 3Ernexa Therapeutics’ SVP of Finance Sandra Gurrola resigned, effective July 3, 2026.Gurrola will provide part-time transition ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL7qNFjw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646058888","title":"Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2646058888","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646058888?lang=en_us&edition=fundamental","pubTime":"2026-06-25 21:15","pubTimestamp":1782393300,"startTime":"0","endTime":"0","summary":"New platform provides additional perspective on Ernexa's mission to deliver hope for patients through innovative, scalable cell therapies while improving accessibility and affordability Inaugural vide","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/25/3317625/0/en/Ernexa-Therapeutics-Launches-CEO-Corner-to-Provide-Deeper-Insights-into-Company-Progress-Scientific-Strategy-and-Vision-for-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","LENZ","ERNA","BK4139","BK4007","BK4539","PRGS","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644749091","title":"Ernexa expects FDA review of ERNA-101 IND in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2644749091","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644749091?lang=en_us&edition=fundamental","pubTime":"2026-06-17 21:27","pubTimestamp":1781702848,"startTime":"0","endTime":"0","summary":"Ernexa set a Q3 2026 IND submission for ERNA-101, positioning the cell therapy for U.S. regulatory review.The company targets FDA review in Q4 2026, with a first-in-human Phase 1 study planned to start in the same quarter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief on June 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL8yVRgk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644445746","title":"Ernexa Therapeutics - Plans Ind Submission for Erna-101 in Q3 2026 and Phase 1 Study in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2644445746","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644445746?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:48","pubTimestamp":1781700487,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nFWN42O0UH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ernexatx.com","stockEarnings":[{"period":"1week","weight":-0.0597},{"period":"1month","weight":0.3402},{"period":"3month","weight":-0.5676},{"period":"6month","weight":-0.3588},{"period":"1year","weight":-0.8675},{"period":"ytd","weight":-0.8477}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0547},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1215},{"period":"1year","weight":0.1856},{"period":"ytd","weight":0.1282}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.558824,"avgChangeRate":0.130666},{"month":2,"riseRate":0.382353,"avgChangeRate":-0.039626},{"month":3,"riseRate":0.558824,"avgChangeRate":0.018953},{"month":4,"riseRate":0.352941,"avgChangeRate":0.335049},{"month":5,"riseRate":0.411765,"avgChangeRate":0.015195},{"month":6,"riseRate":0.5,"avgChangeRate":0.005635},{"month":7,"riseRate":0.257143,"avgChangeRate":-0.04689},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.016811},{"month":9,"riseRate":0.323529,"avgChangeRate":-0.027842},{"month":10,"riseRate":0.352941,"avgChangeRate":-0.041231},{"month":11,"riseRate":0.5,"avgChangeRate":0.055021},{"month":12,"riseRate":0.323529,"avgChangeRate":-0.050712}],"exchange":"NASDAQ","name":"Eterna Therapeutics Inc.","nameEN":"Eterna Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eterna Therapeutics Inc.(ERNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Eterna Therapeutics Inc.(ERNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Eterna Therapeutics Inc.,ERNA,Eterna Therapeutics Inc.股票,Eterna Therapeutics Inc.股票老虎,Eterna Therapeutics Inc.股票老虎国际,Eterna Therapeutics Inc.行情,Eterna Therapeutics Inc.股票行情,Eterna Therapeutics Inc.股价,Eterna Therapeutics Inc.股市,Eterna Therapeutics Inc.股票价格,Eterna Therapeutics Inc.股票交易,Eterna Therapeutics Inc.股票购买,Eterna Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eterna Therapeutics Inc.(ERNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Eterna Therapeutics Inc.(ERNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}